Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226661 · ClinicalTrials.gov registry record · Phase 2
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT07226661: Recruiting Phase 2 study, sponsored by Supernus Pharmaceuticals.
NCT07226661 is a Phase 2 study that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 230 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226661, a Phase 2 study, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
Primary Outcome
MADRS is a 10-item scale (Reported sadness, Apparent sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimist thoughts, and Suicidal thoughts) where each item is scored from 0 to 6. The total score is the sum of the 10 items ranging from 0 to 60 where higher scores indicate more severe depression, and lower scores are better outcomes.
Interventions
- DRUG Placebo
- DRUG SPN-821 2400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
What NCT07226661 shows while recruiting
NCT07226661 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07226661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07226661 about?
NCT07226661 is a clinical study titled "Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder". This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
What is the current status of trial NCT07226661?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2026-01-19. Estimated completion is 2027-01-31.
What interventions are being tested in trial NCT07226661?
The interventions under investigation include: Placebo (DRUG), SPN-821 2400 mg (DRUG).
Who is sponsoring clinical trial NCT07226661?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07226661's enrollment target sits among peer trials
230 257th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI